Analyst Upgrades: Facebook Inc, FireEye Inc, and Juno Therapeutics Inc

Analysts upwardly revised their ratings on Facebook Inc (FB), FireEye Inc (FEYE), and Juno Therapeutics Inc (JUNO)

Aug 18, 2015 at 8:55 AM
facebook twitter linkedin


Analysts are weighing in today on social network Facebook Inc (NASDAQ:FB), cybersecurity firm FireEye Inc (NASDAQ:FEYE), and drugmaker Juno Therapeutics Inc (NASDAQ:JUNO). Here's a quick roundup of today's bullish brokerage notes on FB, FEYE, and JUNO.

  • FB saw its price target raised to $120 from $105 at MKM Partners. The bullish brokerage attention is par for the course, as 27 of 29 analysts rate Facebook Inc a "buy" or better -- with not a single "sell" recommendation in sight -- while its consensus 12-month price target of $111.27 sits in uncharted territory. The optimism contrasts sharply with what we're seeing in the options pits, where the stock's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.58 ranks in the 90th percentile of its annual range. On the charts, FB has advanced over 20% year-to-date to trade at $93.93, and less than one month ago touched a record high of $99.24. A capitulation among the bearish holdouts in options land could provide another catalyst higher.

  • Imperial Capital boosted its opinion on FEYE to "outperform" from "in-line," and raised its price target to $55 from $45.50. As such, the shares are pointed 1.2% higher ahead of the bell, and could add to their more than 38% year-to-date gain, as of Monday's close at $43.65. As with FB, FireEye Inc faces skepticism among option traders. The stock's 10-day ISE/CBOE/PHLX put/call volume ratio rests at a 12-month high of 0.87. Should these bears begin to hit the exits, FEYE could catch a tailwind.

  • FBR Capital Markets initiated coverage on JUNO with an "outperform" rating, despite the stock being down 20.4% year-to-date. Thanks to the bullish attention, though, the security is poised to pop nearly 2% at the open. On the sentiment front, positivity is nothing new for Juno Therapeutics Inc -- among the brokerage bunch, at least. Eighty percent of covering analysts consider the shares worthy of a "strong buy" rating, with not a single "sell" assessment to be found. Plus, JUNO's consensus 12-month price target of $63.80 stands at a 53.5% premium to last night's settlement at $41.56.

Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earnings guide for Q3 before it's too late!


  
 
Special Offers from Schaeffer's Trading Partners